Nevertheless, further studies are required to confirm the association between MUTYH-monoallelic variants and risk of breast cancer, which can provide additional knowledge for assessing the patient’s risk and the potential of developing a new therapeutic target [39]. This evidence concerns the gene MUTYH and breast cancer.